Repurposing Tecfidera for cancer

@article{Booth2016RepurposingTF,
  title={Repurposing Tecfidera for cancer},
  author={L. Booth and M. Malkin and P. Dent},
  journal={Aging (Albany NY)},
  year={2016},
  volume={8},
  pages={1289 - 1290}
}
  • L. Booth, M. Malkin, P. Dent
  • Published 2016
  • Medicine
  • Aging (Albany NY)
  • The compound dimethyl fumarate (DMF) has been an approved drug in Europe for several decades as a therapeutic for psoriasis and relapsing-remitting multiple sclerosis (MS). More recently, the drug has been approved in The United States as an MS treatment (Tecfidera®). Upon ingestion, the drug is rapidly metabolized into the biologically active form of the agent, mono methyl fumarate (MMF); the biological actions of DMF and MMF in vitro are not identical, for example DMF modulates NFκB activity… CONTINUE READING
    4 Citations
    Perspectives on the Clinical Development of NRF2-Targeting Drugs.
    Functional analysis of Cullin 3 E3 ligases in tumorigenesis.
    • J. Cheng, J. Guo, +4 authors W. Wei
    • Biology, Medicine
    • Biochimica et biophysica acta. Reviews on cancer
    • 2018
    • 27